Publications
March 5, 2023
Immuneering Presents Preclinical Data with Lead Program IMM-1-104 Supporting Universal-RAS Activity
Broad response demonstrated through deep cyclic inhibition of MAPK pathway, independent of specific RAS mutation Phase 1/2a clinical trial with IMM-1-104 underway in patients with advanced solid tumors harboring RAS…
November 10, 2022
Cyclic disruption of the mitogen-activated protein kinase (MAPK) pathway by the Dual MEK inhibitor, IMM-6-415, enhances PD-1 and CTLA-4 checkpoint blockade in RAS mutant tumors
KRAS is the most frequently altered RAS gene (~85%) and is often mutated in pancreatic ductal adenocarcinoma (PDAC; 95%), non-small cell lung cancer (NSCLC; 40%) and colorectal cancer (CRC; 45%)1….
May 26, 2022
Translational Modeling for Patients with RAS Mutant Tumors: Profiling the Dual-MEK Inhibitor IMM-1-104 in a Humanized 3D Assay
Background: Elevated RAS-RAF-MEK-ERK (MAPK pathway) signaling is observed in over half of all solid human tumors, and mutations in RAS or RAF account for a large fraction. Given MEK’s unique…
Head-to-Head Comparison of the Dual-MEK Inhibitor IMM-1-104 versus Sotorasib or Adagrasib in KRAS Mutant Pancreatic Tumors
Background: KRAS mutations are common in pancreatic ductal adenocarcinoma (PDAC). While 90% of PDAC tumors display activating mutations in KRAS, only ~2% are G12C, a specific KRAS mutation targeted by…
January 6, 2022
Head-to-head comparison of the dual-MEK inhibitor IMM-1-104 versus binimetinib in NRAS mutant melanoma models
Title: Head-to-head comparison of the dual-MEK inhibitor IMM-1-104 versus binimetinib in NRAS mutant melanoma models Date: January 6, 2022 Presenter: Peter King, Ph.D., Immuneering Vice President, Head of Discovery Virtual…
January 3, 2022
Assessing reproducibility of inherited variants detected with short-read whole genome sequencing
Background Reproducible detection of inherited variants with whole genome sequencing (WGS) is vital for the implementation of precision medicine and is a complicated process in which each step affects variant…
Journal: Genome Biology
December 10, 2021
FDA-led consortium studies advance quality control of targeted next generation sequencing assays for precision oncology
Abstract: Cancer is the second leading cause of mortality worldwide despite tremendous advances in treatment. The promise of precision oncology depends on accurate characterization of tumor mutations and subsequent therapy selection….
Journal: Precision Cancer Medicine
November 17, 2021
Reporting guidelines for human microbiome research: the STORMS checklist
The particularly interdisciplinary nature of human microbiome research makes the organization and reporting of results spanning epidemiology, biology, bioinformatics, translational medicine and statistics a challenge. Commonly used reporting guidelines for…
Journal: Nature Medicine
November 3, 2021
Advancing NGS quality control to enable measurement of actionable mutations in circulating tumor DNA
Despite an increasing demand for precision medicine enabled by NGS measurement of actionable mutations in circulating tumor DNA (ctDNA) specimens, the ability to reliably measure and report low-frequency mutations using…
Journal: Cell Reports
October 7, 2021
IMM-1-104: a novel, oral, selective dual-MEK inhibitor that displays broad antitumor activity and high tolerability across RAS and RAF mutant tumors in vivo
Virtual poster presented at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, October 7-10, 2021 Poster #: P252, Presenter: Brett Hall, Ph.D., Immuneering Chief Scientific Officer
Page 2 of 9
